Regenxbio

RGNX · NASDAQ

$7.40+$0.25 (+3.50%)TodayMarket closed · Oct 20, 7:34 PM ET

Prev close $7.15

About RGNX

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company is headquartered in Rockville, Maryland and currently employs 371 full-time employees. The company went IPO on 2015-09-17. The firm has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address an array of diseases. The company is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. The company is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. The company is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The company is developing RGX-121 for the treatment of Mucopolysaccharidosis type II (MPS II), and RGX-111 to treat Mucopolysaccharidosis Type I.

Employees: 371
Headquarters: Rockville, Maryland
Listed: Sep 17, 2015
Sector: Health Care
Industry: Biotechnology
Website: regenxbio.com

Leadership

Regenxbio executives
Name	Title	Since	Age
Kenneth Mills	—	2009	50
Curran Simpson	—	2015	63
Mitchell Chan	—	—	44
Craig Malzahn	—	—	52
Olivier Danos	—	—	67
Patrick Christmas	—	—	54
Stephen Pakola	—	—	56
Daniel Tasse	—	—	65
Allan Fox	—	—	77
Jean Bennett	—	—	70
Alexandra Glucksmann	—	—	66
A. N. Karabelas	—	—	72
George Migausky	—	—	70
David Stump	—	—	75
Jennifer Zachary	—	—	47

Revenue by product and region

Fiscal year ended Dec 31, 2025: $170.44M total revenue

By product

License and Service [Member]$156.27M91.7%
Service [Member]$14.17M8.3%

Suppliers and customers

Price correlation is over one year: 1 means the stocks move together, -1 opposite

Regenxbio suppliers and customers
Company	Relationship	Country	Correlation
Ultragenyx Pharmaceutical RARE	Supplier and customer	US	0.83
uniQure QURE	Supplier and customer	NL	0.82
Clearside Biomedical CLSD	Supplier and customer	US	0.77
Rocket Pharmaceuticals RCKT	Supplier and customer	US	0.76
Lysogene LYS.PA	Supplier and customer	FR	0.66
FUJIFILM Holdings	Supplier and customer	JP	0.59
Sarepta Therapeutics SRPT	Supplier and customer	US	0.49
Takeda Pharmaceutical	Supplier and customer	JP	0.12
Novartis NOVN.SW	Supplier and customer	CH	-0.14
Astellas Pharma	Supplier and customer	JP	-0.16

Similar companies

Companies in the same industry as Regenxbio

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.